# Esperion Therapeutics share price (Esperion Therapeutics, Inc., ESPR)

> Esperion Therapeutics, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. ESPR · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 10 July 2026. Page: https://www.sectoralpha.in/us/stocks/espr

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.18 (+167.2% in a year)
- Revenue (Mar 2026): $80.1 M (+23.2% on a year ago)
- Profit (Mar 2026): −$25.2 M
- Operating margin: −8.2% (+25.8 points on a year ago)
- ROE: 8%, FY25
- ROIC: 23.5%, against a 11.0% cost of capital: +12.5 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Esperion Therapeutics share price? Esperion Therapeutics, Inc.'s share price was $3.18 at the close on 10 July 2026. That is 4.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $4, and at that close it sat 70% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 6 weeks in a row. Over the last 1 year the share price moved +167% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Esperion Therapeutics pay? Esperion Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Esperion Therapeutics on? Esperion Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Esperion Therapeutics profitable? Esperion Therapeutics, Inc. posted a net loss of $25.2 M in the Mar 2026 quarter. The full FY25 year was a loss of $22.7 M. That loss is 31.5% of the quarter's revenue. The same quarter a year earlier lost $40.5 M. 10 of the last 12 reported quarters were loss-making. ## How much revenue does Esperion Therapeutics make, and is it growing? Esperion Therapeutics, Inc. reported $80.1 M of revenue in the Mar 2026 quarter, +23.2% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 4 years it has grown 50.6% a year on average. The last full year, FY25, came in at $403 M. The last four reported quarters add to $418 M. FY25 revenue was $403 M, +21.3% on the year before. Recent pace: the last four quarters grew +61.9% on average, against 50.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +61.1%, against +34.9% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Esperion Therapeutics keep? Esperion Therapeutics, Inc.'s operating margin was −8.2% in the Mar 2026 quarter, 25.8 percentage points higher than the same quarter a year ago. Across 5 years it has been between −272.1% and 16.4%. The latest quarter is within that range. Why the margin moved: operating margin changed +25.8 percentage points on the year while gross margin changed +13.4 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Esperion Therapeutics' profit turning into cash? Esperion Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $13.1 M of cash, against −$22.7 M of profit. After null of spending on assets, free cash was −$13.1 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Esperion Therapeutics' cash go? Esperion Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $317 K on assets over the last 1 years. Averaged over those years that is 0.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $317 K over the last 1 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Esperion Therapeutics' P/E ratio, and how does it compare with its own history? Esperion Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Esperion Therapeutics, Inc. at 2.0× its FY25 revenue of $403 M. The P/E comes back here once profit turns positive. ## Is the Esperion Therapeutics business getting better or worse? Esperion Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Esperion Therapeutics earn on its capital? Esperion Therapeutics, Inc. earned a ROE of 8% in FY25. Its return on capital used (ROIC) is 12.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a −5.6% net margin and 0.87× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −5.6% net margin × 0.87× asset turnover × −1.54× leverage (assets divided by equity) ≈ 7.5% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 23.5% − 11.0% = +12.5 percentage points. The 11.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. ## Does Esperion Therapeutics have too much debt? Esperion Therapeutics, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from −2.63 in FY21 to −1.81 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Esperion Therapeutics shareholding pattern? 7.4% of Esperion Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 1.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Esperion Therapeutics from balance-sheet trouble? For Esperion Therapeutics, Inc., the Z-score is −2.72. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −2.72 is inside the danger zone, so the balance sheet is a real risk. ## How does Esperion Therapeutics rank in its industry? There is no score against its industry: Esperion Therapeutics, Inc. is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Esperion Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Esperion Therapeutics in size? Esperion Therapeutics is the 34th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Cronos Group Inc., Amphastar Pharmaceuticals, Inc. and Harrow, Inc. Just below it: Collegium Pharmaceutical, Inc., Ironwood Pharmaceuticals, Inc. and Evotec SE. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Cronos Group Inc.](https://www.sectoralpha.in/us/stocks/cron) $1.3 billion
2. [Amphastar Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amph) $1.2 billion
3. [Harrow, Inc.](https://www.sectoralpha.in/us/stocks/hrow) $1.1 billion
4. Esperion Therapeutics, Inc. $819 million
5. [Collegium Pharmaceutical, Inc.](https://www.sectoralpha.in/us/stocks/coll) $773 million
6. [Ironwood Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/irwd) $578 million
7. [Evotec SE](https://www.sectoralpha.in/us/stocks/evo) $569 million

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Cryoport, Inc.](https://www.sectoralpha.in/us/stocks/cyrx) $822 million · Integrated Freight & Logistics
2. [Peapack-Gladstone Financial Corporation](https://www.sectoralpha.in/us/stocks/pgc) $821 million · Banks - Regional
3. Esperion Therapeutics, Inc. $819 million
4. [TETRA Technologies, Inc.](https://www.sectoralpha.in/us/stocks/tti) $819 million · Conglomerates
5. [Postal Realty Trust, Inc.](https://www.sectoralpha.in/us/stocks/pstl) $818 million · REIT - Office

## What else do people ask about Esperion Therapeutics? ### What were Esperion Therapeutics's latest quarterly results? Esperion Therapeutics, Inc. reported revenue of $80.1 M and a net loss of $25.2 M for the Mar 2026 quarter. Earnings per share were −$0.10. The operating margin was −8.2%, 25.8 percentage points higher than a year earlier (as of 10 July 2026). ### What is Esperion Therapeutics's market cap? Esperion Therapeutics, Inc.'s market capitalisation is $819 M at a stock price of $3.18. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 10 July 2026). ### How is Esperion Therapeutics performing? Esperion Therapeutics, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 6 weeks running. This describes what the data did, not a rating (as of 10 July 2026). ### Will Esperion Therapeutics's stock price go up? This page does not forecast Esperion Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $3.18. Nobody can reliably say which way a price will move, and this site does not try (as of 10 July 2026). ### Where is Esperion Therapeutics in its business cycle? Esperion Therapeutics, Inc.'s FY25 operating margin was 15.0%, against a 5-year range of −272.1% to 16.4%: the middle of its own range, neither a peak nor a low. The latest quarter was −8.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 10 July 2026). ### What could break the Esperion Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 10 July 2026). ### Is Esperion Therapeutics a stock worth studying right now? What the numbers show: Esperion Therapeutics, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 10 July 2026). This is research, not advice. We’re not SEBI-registered.